← Leaderboards
Bruce Williams
University Of New Mexico
$67,299
Attributed
$67,299
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$67,299 · 3
By mechanism
M01$67,299 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of New Mexico
Same institution · by research overlap
- Hillard S Kaplan$9,308,406
- Mark R Burge$7,348,770
- David S Schade$14,177,133
- Juan Bustillo$587,257
- Diane Goade$1,196,947
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchAids TherapyAidsChemopreventionCytomegalovirusDietary ProteinsDietary SupplementsDrug Administration Rate /DurationDrug Administration RoutesDrug Screening /EvaluationHelper T LymphocyteHiv InfectionsHuman Immunodeficiency Virus 1ImmunotherapyInterleukin 2Leukocyte CountNutrient RequirementOpportunistic InfectionsRecombinant ProteinsWeight LossAntiaids AgentAntiviral Agents
Grant awards (6)
OPEN LABEL TRIAL OF CALORIC SUPPLEMENTS WITH PEPTIDES IN AIDS$22,433
M01 · FY2000 · RR
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL IN PROLONGING SURVIVAL OF HIV PTS$22,433
M01 · FY2000 · RR
IMPACT OF TWO DOSES OF SUBCUTANEOUS RECOMBINANT IL 2 (PROLEUKIN)$22,433
M01 · FY2000 · RR
OPEN LABEL TRIAL OF CALORIC SUPPLEMENTS WITH PEPTIDES IN AIDS$0
M01 · FY2000 · RR
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL IN PROLONGING SURVIVAL OF HIV PTS$0
M01 · FY2000 · RR
IMPACT OF TWO DOSES OF SUBCUTANEOUS RECOMBINANT IL 2 (PROLEUKIN)$0
M01 · FY2000 · RR